Our team

Reaching goals together.

You don’t achieve great goals alone. That’s why there are many bright minds behind WMT, bringing research against cancer a little closer to its goal every day.

Learn more about the valuable work of our team members here.


Dr. Claus Kremoser

Chief Executive Officer & Executive Board

Claus has earned his degree in biochemistry from the University of Tübingen and performed his PhD work in the group of Friedrich Bonhoeffer at the Max-Planck-Institue for Developmental Biology.

He was crucially involved in LION bioscience´s IPO in 2000 raising a European record sum of 220 M Euros. Together with Thomas Hoffmann he co-founded Phenex Pharmaceuticals AG in 2002 which became a very successful biotech company by closing two major asset sales to Janssen (2012) and Gilead (2014) with a total value of more than 600 million US $.

In summer 2020, Claus, together with eight experienced drug discovery scientists and Yves Guillermet from the business side co-founded WMT AG to continue his track record as a serial entrepreneur. Claus serves as the CEO of WMT.

Yves Guillermet

Chief Operations Officer & sole authorized signatory

Yves has more than 25 years experience in general management with increasing responsibilities in human resources, controlling and finance, project management and consulting. Equipped with degrees in business adminstrations and mathematics from the University of Lyon and an officer training from the French Army he filled various positions at companies such as Decathlon, Claas, Bausch & Lomb and Novaliq.

Yves is a major shareholder and cofounder of WMT AG and serves as its current COO.

Key scientists

Dr. George Reid

Senior Director Drug Discovery Biology

George has more than 25 years experience in academic research and in large pharma applied drug discovery. He spent long years at the EMBL and as group leader at the IMB in Mainz but he also has substantial experiences in the industry with positions at Pfizer and Phenex AG. George´s research interests for many years have been at the crossroads of transcriptional control and cancer. He has published 54 peer-reviewed papers including first author positions in Cell and 2x Nature and his scientific work yielded 6.381 quotations. George and Iryna together have performed the groundbreaking work for the Pirin modulators.

Dr. Christoph Steeneck

Senior Director Medicinal Chemistry

Christoph has a diploma and a PhD degree in synthetic organic chemistry. He has 19 years industry experience in drug discovery and during his professional career at Alantos and at Phenex (from 2009 to 2020) he has contributed to four clinical stage compounds. Christoph has authored 12 peer-reviewed articles and is inventor on 28 patent families. With his outstanding experience and excellence he oversees the medicinal chemistry efforts at WMT.

Dr. Iryna Charapitsa

Head of Discovery Biology

Irynas has earned her PhD jointly from the EMBL and the Heidelberg University and she has spent several years as postdoc at the Max-Planck-Institute, the EMBL and the IMB in Mainz. She is a long standing collaborator of George and they both have pioneered the Pirin modulator approach. Iryna has 15 years experience in molecular biology with a focus on transcriptional regulation and epigenetics.

Supervisory board

Dr. Siegfried Bialojan

Chairman of Supervisory Board

Dr. Martin Pfister

Deputy Chairman of the Supervisory Board

Prof. Dr. Stephan Sigrist

Member of Supervisory Board

Dr. Julia Schaft

Member of Supervisory Board

Dr. Oliver Schlüter

Member of Supervisory Board

Dr. Guanghui Hu

Member of Supervisory Board